Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study

The Screening for Osteoporosis in Older Women for the Prevention of Fracture (SCOOP) study was a community‐based screening intervention in women aged 70 to 85 years in the United Kingdom. In the screening arm, licensed osteoporosis treatments were recommended in women identified to be at high risk of hip fracture using the FRAX risk assessment tool (including bone mineral density measurement). In the control arm, standard care was provided. Screening led to a 28% reduction in hip fractures over 5 years. In this planned post hoc analysis, we wished to examine for interactions between screening effectiveness on fracture outcome (any, osteoporotic, and hip fractures) on the one hand and baseline FRAX 10‐year probability of hip fracture on the other. All analyses were conducted on an intention‐to‐treat basis, based on the group to which women were randomized, irrespective of whether screening was completed. Of 12,483 eligible participants, 6233 women were randomized to screening, with treatment recommended in 898 (14.4%). No evidence of an effect or interaction was observed for the outcomes of any fracture or osteoporotic fracture. In the screening arm, 54 fewer hip fractures were observed than in the control arm (164 versus 218, 2.6% versus 3.5%), and commensurate with treatment being targeted to those at highest hip fracture risk, the effect on hip fracture increased with baseline FRAX hip fracture probability (p = 0.021 for interaction); for example, at the 10th percentile of baseline FRAX hip probability (2.6%), there was no evidence that hip fractures were reduced (hazard ratio [HR] = 0.93; 95% confidence interval [CI] 0.71 to 1.23), but at the 90th percentile (16.6%), there was a 33% reduction (HR = 0.67; 95% CI 0.53 to 0.84). Prior fracture and parental history of hip fracture positively influenced screening effectiveness on hip fracture risk. We conclude that women at high risk of hip fracture based on FRAX probability are responsive to appropriate osteoporosis management. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

[1]  C. Cooper,et al.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.

[2]  J. Kanis,et al.  The Effect of Abaloparatide‐SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[4]  C. Cooper,et al.  Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting , 2017, Osteoporosis International.

[5]  C. Cooper,et al.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures , 2017, Osteoporosis International.

[6]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[7]  J. Kanis,et al.  FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.

[8]  J. Kanis,et al.  Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.

[9]  E. McCloskey,et al.  A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base , 2015, Osteoporosis International.

[10]  J. Kanis,et al.  Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  T. Peters,et al.  Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. , 2012, Family practice.

[12]  T. Peters,et al.  A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study , 2012, Osteoporosis International.

[13]  J. Kanis,et al.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® , 2011, Osteoporosis International.

[14]  J. Kanis,et al.  A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.

[15]  J. Kanis,et al.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.

[16]  J. Kanis,et al.  Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.

[17]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[18]  O Johnell,et al.  A family history of fracture and fracture risk: a meta-analysis. , 2004, Bone.